Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shalini L Kulasingam

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Preventive Medicine|May 5, 2015
The significantly lower risk of cervical cancer at and after the recommended age to begin and end screening compared to breast and colorectal cancerHilary K Whitham, Shalini L Kulasingam
JAMA|August 14, 2003
Potential health and economic impact of adding a human papillomavirus vaccine to screening programsShalini L Kulasingam, Evan R Myers
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Economic evaluations of human papillomavirus vaccinesRuanne V Barnabas, Shalini L Kulasingam
Current Infectious Disease Reports|April 5, 2001
Will New Human Papillomavirus Diagnostics Improve Cervical Cancer Control Efforts?Shalini L. Kulasingam, Laura A. Koutsky
Vaccine|October 27, 2007
Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.SShalini L Kulasingam, Sonia Pagliusi, Evan Myers
Spatial and Spatio-Temporal Epidemiology|June 4, 2014
Spatial patterns of human papillomavirus-associated cancers within the state of Minnesota, 1998-2007Erik J Nelson, John Hughes, Shalini L Kulasingam
Journal of Lower Genital Tract Disease|March 23, 2013
Screening for cervical cancer: a modeling study for the US Preventive Services Task ForceShalini L Kulasingam, Laura J Havrilesky, Rahel Ghebre, et al.
Infection Control and Hospital Epidemiology|September 21, 2018
Cost-effectiveness of pre-operative Staphylococcus aureus screening and decolonizationSusan E Kline, Erinn C Sanstead, James R Johnson, et al.
Gynecologic Oncology|March 26, 2005
FDG-PET for management of cervical and ovarian cancerLaura J Havrilesky, Shalini L Kulasingam, David B Matchar, et al.
Cost Effectiveness and Resource Allocation : C/E|February 19, 2008
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysisShalini L Kulasingam, Steve Benard, Ruanne V Barnabas, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Preventive Medicine|May 5, 2015
The significantly lower risk of cervical cancer at and after the recommended age to begin and end screening compared to breast and colorectal cancerHilary K Whitham, Shalini L Kulasingam
JAMA|August 14, 2003
Potential health and economic impact of adding a human papillomavirus vaccine to screening programsShalini L Kulasingam, Evan R Myers
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Economic evaluations of human papillomavirus vaccinesRuanne V Barnabas, Shalini L Kulasingam
Current Infectious Disease Reports|April 5, 2001
Will New Human Papillomavirus Diagnostics Improve Cervical Cancer Control Efforts?Shalini L. Kulasingam, Laura A. Koutsky
Vaccine|October 27, 2007
Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.SShalini L Kulasingam, Sonia Pagliusi, Evan Myers
Spatial and Spatio-Temporal Epidemiology|June 4, 2014
Spatial patterns of human papillomavirus-associated cancers within the state of Minnesota, 1998-2007Erik J Nelson, John Hughes, Shalini L Kulasingam
Journal of Lower Genital Tract Disease|March 23, 2013
Screening for cervical cancer: a modeling study for the US Preventive Services Task ForceShalini L Kulasingam, Laura J Havrilesky, Rahel Ghebre, et al.
Infection Control and Hospital Epidemiology|September 21, 2018
Cost-effectiveness of pre-operative Staphylococcus aureus screening and decolonizationSusan E Kline, Erinn C Sanstead, James R Johnson, et al.
Gynecologic Oncology|March 26, 2005
FDG-PET for management of cervical and ovarian cancerLaura J Havrilesky, Shalini L Kulasingam, David B Matchar, et al.
Cost Effectiveness and Resource Allocation : C/E|February 19, 2008
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysisShalini L Kulasingam, Steve Benard, Ruanne V Barnabas, et al.
Pageof 4